Harmony Biosciences Posts Record Q2 Revenue of $261M and Advances Best-in-Class Orexin Agonist BP-205
HRMY sits 46% above its 52-week low of $25.52.
Summary
Record Q2 2026 WAKIX revenue of $261.3M (+30% YoY) was posted by Harmony Biosciences, $1B+ guidance was reiterated, and promising Phase 1 data for BP-205, a potential best-in-class orexin-2 agonist, were unveiled. A rich pipeline with multiple catalysts through 2028 is being advanced.
Key Events · Earnings and Guidance · HRMY
-
Record Q2 Revenue, Guidance Reiterated
Driven by strong demand and 450 net patient adds, WAKIX net product revenue reached $261.3M in Q2 2026, a 30% increase year-over-year. Full-year 2026 guidance of $1.0B–$1.04B was reaffirmed.
-
BP-205 Phase 1 Data Supports Best-in-Class Potential
Single ascending dose data showed rapid absorption (Tmax 30–75 min), a ~25h half-life supporting once-daily dosing, and a favorable safety profile with no serious adverse events. BP-205 is the most potent OX2R agonist in clinical development.
-
Pipeline Catalysts Stacked Through 2028
The pitolisant GR NDA was accepted with a PDUFA date of April 1, 2027; Phase 3 topline data for pitolisant HD and EPX-100 are expected in 2027; and BP-205 Phase 2 trials in multiple CNS indications are planned for mid-2027.
-
Strong Balance Sheet Supports Growth
As of June 30, 2026, cash, cash equivalents and investments totaled $962.5M, providing ample capacity for business development and pipeline investment.
Analysis · HRMY · Life Sciences
A record quarter was delivered by Harmony Biosciences, with WAKIX net revenue climbing 30% year-over-year to $261.3 million, while full-year guidance of $1.0–$1.04 billion was reiterated. Encouraging Phase 1 SAD data for BP-205, its orexin-2 receptor agonist, were also shared, demonstrating rapid absorption, once-daily dosing potential, and a clean safety profile — reinforcing its potential as a best-in-class therapy across multiple CNS indications. With $962.5 million in cash and a catalyst-rich pipeline (pitolisant GR PDUFA in April 2027, Phase 3 data for pitolisant HD and EPX-100 in 2027), the company is well-positioned for sustained growth. The strong commercial execution and pipeline progress come despite recent CFO turnover, underscoring operational resilience.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.6% of the 1155 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HRMY was trading at $37.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $25.52 to $40.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.